GenScript establishes Korean legal entity and accelerates sales activities

GenScript Biotech Korea Ltd.

PR92117

 

SEOUL, South Korea, Oct. 5, 2021 /PRNewswire=KYODO JBN/ --

 

GenScript, a global biotech company, recently completed the establishment of a

legal entity called "GenScript Biotech Korea Ltd." and began to strengthen its

sales activities in Korea in earnest.

 

GenScript Biotech Korea Ltd. has built a nest at IKP (Invest Korea Plaza) in

Heolleung-ro, Seocho-gu, Seoul. The main purpose of the establishment of the

company is to support Korean customers in the research and development,

importation, marketing, and distribution of reagent products and life science

technology service.

 

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong

Stock Exchange in 2015. GenScript's business operations span over 100 countries

and regions worldwide with legal entities located in the US, Mainland China,

Hong Kong, Japan, Singapore, the Netherlands and Ireland. GenScript provides

premium, convenient and reliable services and products for over 100,000

customers.

 

Through the development of various technologies, such as advances in cell

therapy and creation of a customizable CRO solutions platform, GenScript has

established itself as a global leader in biotechnology. In 2019, the business

field was expanded from the existing CRO business to biopharmaceutical CDMO

services, through GenScript ProBio, which is establishing partnerships with a

series of biotech companies in Korea.

 

In this regard, Yuyu Hu, Head of Business Development Korea has said, "We

expect the establishment of a Korean legal entity to spur sales activities and

strengthen our Korean business in earnest."

 

For more information, please visit GenScript Biotech's official website

https://www.genscript.com.

 

SOURCE:  GenScript Biotech Korea Ltd.

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中